Dr. Kevin J. Scanlon’s background includes: academic medicine, senior management in the pharmaceutical industry, CEO of start-up biotechnology companies and an educator for graduate students interested in combining science and business. He has the experience and expertise to enhance these relationships between academics, investors and start-up enterprises in the life science community. Some examples of his experiences includes the following:

• Currently, he is the Emeritus Director of the Pasadena Angels. He has been mentoring and supporting entrepreneurs through the investment community (Pasadena Angels and the Tech Coast Angels of Los Angeles). These organizations support entrepreneurs with seed investments for their novel technology. (Investment Community)
• He is a faculty educator for graduate business students involved in a business of science program to understand the life science industry. UCLA Faculty advisor for the FEMBA Global Access Program (anderson.ucla.edu/gap.xml) and the EMBA Strategic Management Research Program at UCLA School of Management. EMBA Flyer in Adobe PDF Format. (Teaching)
• He has worked with entrepreneurs, the investment community and international governments in Europe, Asia and New Zealand to create an innovative culture around the intellectual property from their academic institutions. (Events)
• Dr. Scanlon was co-founder and former CEO of the cancer diagnostic company, Melanoma Diagnostics (MDx). The product, a six-gene assay that discriminates melanoma from moles, was sold to Myriad Genetics Salt Lake City, Utah in December 2010 (see below). MDx is one of three early stage biotechnology companies that he has helped spin-out from academic technology. (Entrepreneur).
  
  Download the official press release in Adobe PDF Format.
• As a Pharmaceutical Industry-Vice President at Berlex-Schering AG, (Berlin, Germany) he was responsible for their international cancer (genomic) research program in the US, Europe and Asia. (Industry)
• Dr. Scanlon has also been a lead investigator on government and foundation grants, co-editor and co-founder of the Nature journal "Cancer Gene Therapy", authored over 135 original scientific articles and has nine issued US Patents from his research. (Science)